Keyphrases
Anabolic Steroids
63%
Body Mass Index
57%
Cancer Patients
57%
Clear Cell Carcinoma
57%
Clinical Manifestations
19%
Convalescence
19%
Doping Control
57%
Early Postoperative Complications
28%
Endometrial Cancer
57%
Epithelial Ovarian Cancer
57%
Exceptional Characters
19%
Follicular Carcinoma
19%
Follow-up Control
19%
Glucuronide
38%
Histology
19%
Hospital Admission
28%
Immunohistochemical Study
19%
Interval Debulking Surgery
57%
Laparoscopy
90%
Laparotomy
30%
Local Processes
19%
Malignant Struma Ovarii
57%
Malignant Transformation
57%
Microorganisms
57%
Neoadjuvant Chemotherapy
40%
Oral Testosterone
57%
Overall Survival
44%
Pathological Examination
19%
Peripheral Tissues
19%
Peritoneal Cancer
57%
Plasma Markers
57%
Pre-surgical
19%
Primary Debulking Surgery
57%
Radiography
19%
Recurrence-free Survival
28%
Resectability
57%
Retrospective Cohort Study
22%
Stage IIIC
57%
Steroid Profile
69%
Struma Ovarii
38%
Surgery Groups
24%
Surgical Approach
57%
Surgical Staging
61%
Teratoma
19%
Testosterone
63%
Testosterone Undecanoate
57%
Tubal Cancer
57%
Uncertain Prognosis
19%
Urinary Markers
57%
Urine Contamination
57%
Medicine and Dentistry
Bleeding
14%
Body Mass Index
57%
Clear Cell
14%
Clear Cell Carcinoma
57%
Convalescence
14%
Cytoreductive Surgery
57%
Debulking Surgery
57%
Dentigerous Cyst
57%
Follicular Carcinoma
14%
Gynecology
14%
Histology
14%
Krukenberg Tumor
57%
Laparoscopic Surgery
100%
Laparotomy
22%
Malignant Transformation
42%
Minimally Invasive Procedure
14%
Neoadjuvant Chemotherapy
20%
Neoplasm
8%
Obstetrics
14%
Operative Blood Loss
14%
Ovarian Tumor
14%
Overall Survival
40%
Pelvic Tumor
14%
Peritoneum Cancer
57%
Postoperative Complication
28%
Prevalence
14%
Progression Free Survival
8%
Recurrence Free Survival
28%
Retroperitoneal Lymph Node Dissection
14%
Retrospective Cohort Study
18%
Surgical Approach
57%
Thyroglobulin
14%
Uterine Cancer
57%